Radio and PodcastRadio and PodcastLive Radio & Podcasts
Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] artwork
Health

Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]

MDS Professional Report by PI Media

Mar 30, 202130:19Health

PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third o...

About This Episode

Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] is an episode from MDS Professional Report by PI Media. PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)T...

Podcast

This episode belongs to MDS Professional Report.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Mar 30, 2021, 30:19 long, audio available.

Questions About This Episode

What is Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] about?

PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third of hospitalized adult patients with hematologic malignancy and COVID-19 – dye. ⦁ No need to withhold anti-cancer treatment from these patients. Paper 2Authors: P. Fenaux; U. Platzbecker; A. List and colleagues, multicenterTitle: Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesDescription: Luspatercept, an activin receptor derived agent, improves the anemia in LR-MDS patients. Thus, we have another approved anti-anemic agent in addition to ESAs for these patients. Paper 3Authors: David Henry et al. , multicenter ((Disclosure – I am a co-author)Title: Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin LevelsDescription: Roxadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is another investigated effective agent for the anemia in LR-MDS. Paper 4Title: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLAuthors: M.A. Sekeres, and colleagues, multicenter, multunationalDescription: Pevonedistat, a NEDD8 inhibitor, together with azacitidine, improves the response and prognosis in HR-MDS patients.

Where can I listen to Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]?

You can listen to Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] from?

Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] is an episode from MDS Professional Report by PI Media.

How long is this episode?

This episode is 30:19 long.

When was this episode published?

This episode was published on Mar 30, 2021.

Can I save Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from MDS Professional Report?

Yes. This page shows related episodes from MDS Professional Report when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]?

You can listen to Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report] is from MDS Professional Report by PI Media.

What are the episode details?

Published Mar 30, 2021 and 30:19 long